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Abstract
Background: In humans, mutations in the SEPN1 gene, encoding selenoprotein N (SelN), are
involved in early onset recessive neuromuscular disorders, referred to as SEPN1-related-
myopathies. The mechanisms behind these pathologies are poorly understood since the function
of SelN remains elusive. However, previous results obtained in humans and more recently in
zebrafish pointed to a potential role for SelN during embryogenesis. Using qRT-PCR, Western blot
and whole mount in situ hybridization, we characterized in detail the spatio-temporal expression
pattern of the murine Sepn1 gene during development, focusing particularly on skeletal muscles.
Results: In whole embryos, Sepn1 transcripts were detected as early as E5.5, with expression
levels peaking at E12.5, and then strongly decreasing until birth. In isolated tissues, only mild
transcriptional variations were observed during development, whereas a striking reduction of the
protein expression was detected during the perinatal period. Furthermore, we demonstrated that
Sepn1  is expressed early in somites and restricted to the myotome, the sub-ectodermal
mesenchyme and the dorsal root ganglia at mid-gestation stages. Interestingly, Sepn1 deficiency did
not alter somitogenesis in embryos, suggesting that SelN is dispensable for these processes in
mouse.
Conclusion:  We characterized for the first time the expression pattern of Sepn1  during
mammalian embryogenesis and we demonstrated that its differential expression is most likely
dependent on major post-transcriptional regulations. Overall, our data strongly suggest a potential
role for selenoprotein N from mid-gestation stages to the perinatal period. Interestingly, its specific
expression pattern could be related to the current hypothesis that selenoprotein N may regulate
the activity of the ryanodine receptors.
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Background
Selenium is a rare trace element mainly present in biolog-
ical systems as a selenocysteine (Sec), an amino acid
found in proteins called selenoproteins and encountered
in all lineages of life. Insertion of the Sec residue occurs
through a recoded UGA stop codon which is recognized
by a complex machinery involving a secondary structure
present in the 3'UTR region of the mRNA (Sec Insertion
Sequence, SECIS), which interacts during translation with
specific factors, such as SBP2 (SECIS Binding Protein 2)
and eEFSec (eukaryote Elongation Factor), leading to Sec
insertion rather than termination [1,2]. In mammals,
about 25 selenoproteins have been described [3]. Most of
them are enzymes involved in oxidation-reduction reac-
tions, with the selenocysteine residue(s) usually located in
the catalytic site and conferring a strong enzymatic reactiv-
ity [4,5]. Moreover, most selenoproteins are expressed
early during development [2,6] and for several of them an
essential role in embryogenesis has been established [7-
9]. Selenium deficiency has been associated with different
syndromes, such as Keshan cardiomyopathy, white mus-
cle disease or rigid lamb syndrome, leading to dietary
intake recommendations for humans and livestock [10].
Notably, mutations were identified in the SEPN1 gene,
encoding selenoprotein N (SelN), as the genetic cause for
Rigid Spine Muscular Dystrophy (RSMD1) [11]. This
pathology is characterized by axial weakness, severe scol-
iosis usually requiring surgery, and respiratory insuffi-
ciency due to respiratory muscles weakness and
necessitating mechanical nocturnal ventilation [12].
SEPN1  mutations were subsequently associated with
three other neuromuscular disorders: the classical form of
Multi-minicore Disease (MmD) [13], rare cases of
Desmin-Related Myopathy with Mallory Body-like Inclu-
sions (MB-DRM) [14] and of Congenital Fibre Type Dis-
proportion (CFTD) [15]. These four early onset
autosomal recessive pathologies exhibit clinical and mor-
phological overlaps; they are now grouped and termed
SEPN1-related myopathies (SEPN1-RM).
We showed previously that SelN is a glycoprotein located
in the membrane of the endoplasmic reticulum [16]. In
humans, its expression appeared ubiquitous and was
down-regulated during myoblast differentiation in cul-
ture, and in the transition from foetal to adult tissues [16].
In zebrafish, an early expression of sepn1 was shown dur-
ing embryogenesis, specifically in somites, the tail bud
and the notochord [6,17]. Furthermore, sepn1 zebrafish
mutants obtained by morpholino injection, exhibited
strong developmental defects such as tail malformations,
disorganisation of somite borders, and abnormalities in
muscles development and architecture [17,18]. These
data, as well as the early onset of the human pathology,
clearly pointed to a possible role for SelN during muscle
development. Interestingly, physical and functional inter-
actions between SelN and ryanodine receptors (RyR) were
recently demonstrated, indicating that SelN may regulate
RyR activity in muscles [17,19].
Here, we characterized extensively the expression pattern
of Sepn1 in mouse during pre- and post-natal develop-
ment, in several tissues, particularly in skeletal muscles.
We demonstrated that Sepn1  is expressed early during
mouse embryogenesis and that it is restricted to specific
areas, including muscle precursors, at mid-gestation
stages. In isolated tissues, mild variations of Sepn1 tran-
scripts were detected between ages, whereas the protein
expression was strikingly down-regulated during the peri-
natal period, indicating post-transcriptional regulations
of Sepn1 expression during development.
Results
Spatio-temporal dynamics of Sepn1 expression
In whole embryos, Sepn1 expression was detected by qRT-
PCR as early as E5.5, with higher levels from E9.5 to E12.5
(six and ten fold increase, respectively). We then observed
a five fold reduction of the expression from E12.5 to E18.5
(Figure 1A). This decrease was confirmed at the protein
level by Western blot since SelN was reduced by more
than two fold in E18.5 embryos compared to E12.5 (Fig-
ure 1B).
We then investigated Sepn1 expression in isolated quadri-
ceps, diaphragm and non-skeletal-muscle tissues (brain,
liver, kidney and heart) from late embryonic stages (E15,
E18) to 15 months of age, with an earlier embryonic stage
included for the heart (E13) (Figure 2A). By qRT-PCR,
Sepn1  expression was detected in all tissues, albeit at
barely detectable levels in liver (Figure 2A). Overall, vari-
ations in the mRNA levels observed for the different tis-
sues were limited. Nevertheless, we observed a significant
decrease in expression between E15 and E18 in the brain
and in kidney. In parallel, increased levels were detected
between E18 and postnatal day 1 in diaphragm, heart and
kidney. Lastly, we showed a two fold increase in expres-
sion in the brain, between young (16 weeks) and adult
mice (315 months) and a two fold reduction in kidney,
between the first week of life and older mice (3 weeks to
15 months) (Figure 2A). Interestingly, expression in quad-
riceps and diaphragm did not exhibit the highest levels
and appeared mostly constant. Similar results were
obtained for skeletal muscles isolated from posterior
(soleus + gastrocnemius) and anterior (tibialis anterior +
extensor digitorum longus) hind limb compartments
(data not shown).
We studied the expression of SelN at the protein level by
Western blot, using proteins extracted from isolated tis-
sues from E18 to 15 months of age. Several proteins were
tested for protein loading control; actin and GAPDHBMC Developmental Biology 2009, 9:46 http://www.biomedcentral.com/1471-213X/9/46
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exhibited the least variability between the various devel-
opmental stages (Figure 2B and data not shown). Never-
theless, quadriceps homogenates displayed an increase of
both actin and GAPDH expressions after 15 days of age;
for this tissue, no ideal protein normalization could be
obtained. For all the tissues considered except liver, we
observed a striking reduction in SelN expression between
E18 and postnatal day 1 (about three fold reduction), and
even more so at adult ages when it became barely detecta-
ble (less than 10% compared to E18) (Figure 2B). In pro-
tein extracts from liver, SelN was never detected, even at
E18 (Figure 2B), in keeping with the transcript quantifica-
tions.
In parallel, using mouse C2C12 muscle cells, we observed
a 50% decrease of Sepn1 expression in myotubes after 2
and 3 days of differentiation, compared to myoblasts (Fig-
ure 3A). This reduction was even more marked at the pro-
tein level with a five fold reduction detected in myotubes
compared to myoblasts by Western blot (Figure 3B). This
is in accordance with data previously obtained with
human cells [16].
Specificity of Sepn1 probes
Since no appropriate antibody was available for immuno-
histochemistry, we investigated Sepn1 expression pattern
during early embryogenesis by whole mount in situ
hybridization (ISH). The murine Sepn1 cDNA [GenBank:
NM_029100], 3461 bp in size, contains 12 exons, the in-
frame UGA codon being located in exon 9, and leads to a
protein of 557 residues (Figure 4A). In mouse, no
sequence homology was found with the alternatively
spliced third exon described in human, since this exon
corresponds to a primate specific Alu sequence [11]. Two
Sepn1 probes (Pr1: 573 bp and Pr2: 696 bp) were synthe-
sized from PCR fragments corresponding to the 3' region
of the cDNA (Figure 4A). The corresponding murine tran-
script regions shared more than 85% identity with the
human sequence. We performed Northern blot analysis
with Pr1 and Pr2 probes, using RNA extracted from cul-
tured human fibroblasts from a control subject and a
RSMD1 patient with SEPN1 mRNA degradation due to a
premature termination codon (p.L482fs [20]  Figure 4B).
For both probes, one band corresponding to SEPN1 tran-
scripts was observed in control RNA, but was undetectable
in RNA extracted from the patient, thus validating the spe-
cificity of the probes (Figure 4B and data not shown).
Using mouse RNA extracted from E12 and E18 whole
embryos, we detected only one 3.4 kb band by Northern
blot, which corresponds to the predicted transcript size for
Sepn1 (Figure 4C).
Expression pattern of Sepn1 during embryogenesis
Sepn1  deficient mouse embryos were used as negative
controls for whole mount ISH. The recombinant gene
construct introduced a frame-shift and a premature stop
codon within the coding sequence, leading to a loss of the
functional protein in mutants (Rederstorff et al., manu-
script in preparation). As shown in Figure 5A, Sepn1
expression was barely detectable at the transcript levels in
E12.5 mutant whole embryos (Sepn1-/-) compared to
wild-type (Sepn1+/+), indicative of the Sepn1 mRNA degra-
dation in the model. At the protein level, SelN was
observed in wild-type embryos by Western blot but was
undetectable in mutant samples (Figure 5B).
Identical expression patterns were obtained with Pr1 and
Pr2; results presented in Figure 6 correspond to ISH per-
formed with the Pr1 probe. At the different embryonic
stages tested, no signal could be detected using either
sense probes with wild-type embryos (Figure 6A, panel a
and data not shown) or antisense probes with Sepn1-/-
embryos (Figure 6B, panel i and 6C, panel t). This con-
firmed the specificity of the staining pattern obtained.
In E8.5 whole embryos, we detected Sepn1 expression in
somites and the neural tube, as well as in the mesenchyme
located under the ectoderm, in the head and the branchial
arches of embryos (Figure 6A, panels b-f). At E9.5, a ubiq-
uitous-like staining was observed in whole embryos, with
a stronger expression in somites (Figure 6B, panel g).
Upon vibratome sectioning, the staining was associated
with expression in the sub-ectodermal mesenchyme, as
depicted in forebrain (Figure 6B, panel h). At E10.5 and
E11.5, whole embryos appeared strongly stained in the
dorsal part of the body, the limb buds, the branchial
arches and the head (Figure 6C, panels j-m). Following
Sepn1 expression in whole embryos Figure 1
Sepn1 expression in whole embryos. A: Sepn1 expres-
sion was quantified by qRT-PCR on cDNA from whole 
embryos between E5.5 and E18.5. Normalization is per-
formed on the 18s gene. Expression was detected as early as 
E5.5 and strongly increased until E12.5. From this stage until 
birth, a striking decrease of the expression was observed. *, 
p < 0.05. B: Western blot analysis on 60 μg of proteins from 
E12.5 and E18.5 embryos was carried out using SelN and α-
tubulin (normalization) antibodies. SelN expression was 
reduced more than two fold at E18.5 compared to E12.5.
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Expression of Sepn1 transcript and SelN protein in isolated tissues between late embryonic and post-natal stages Figure 2
Expression of Sepn1 transcript and SelN protein in isolated tissues between late embryonic and post-natal 
stages. A: Sepn1 expression was quantified by qRT-PCR and normalized to the 18s gene. Expression in quadriceps was quan-
tified from E18 to 15 months; in diaphragm, liver, brain and kidney from E15 to 15 months; in heart from E13 to 15 months. 
Only mild variations were detected, including between pre- and postnatal stages. Significant variations are indicated for two 
consecutive points: *, p < 0.05; **, p < 0.01. B: SelN Western blot analyses are shown for quadriceps, diaphragm, heart, liver, 
brain and kidney at stages E18, postnatal day 1, 2 and 6 weeks, 3 and 15 months. SelN was undetectable in liver. Actin was used 
as a reference. Quantifications were normalized on the expression measured at E18 and are presented below the blots. For all 
tissues, a striking reduction of the expression was detected between E18 and postnatal day 1. This decrease was even more 
marked in the following post-natal stages. Statistical analyses were performed between E18 and all other stages (**, p < 0.01). 
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sectioning, we observed expression in the dorsal root gan-
glia (drg). Furthermore, within the somites, the myotome
appeared strongly stained, whereas little to no signal was
detected in the dermomyotome of embryos (Figure 6C,
panels n-q). Moreover, as previously seen, the mesen-
chyme located under the ectoderm exhibited staining,
particularly in the head and limb buds (Figure 6C, panels
r, s), although this signal was weak and required a longer
revelation time as compared to the staining observed in
the myotome and drg.
Interestingly, at all of these stages, we did not observe
staining in the heart by ISH, whereas Sepn1 expression was
detected as early as E13 in this tissue by qRT-PCR. This
could result either from Sepn1 cardiac expression appear-
ing after E11.5, or more likely from the higher sensitivity
of the qPCR technique.
Somitogenesis in Sepn1 deficient murine embryos
Since an early expression of Sepn1  was observed in
somites and defects were reported in somite organisation
and myogenic factors expression in sepn1  morpholino
injected zebrafish embryos [17,18], we specifically inves-
tigated these events in Sepn1-/- embryos. At mid-gestation
stages (E10 and E11.5), ISH performed against the myo-
genic determination factors Myf5,  MyoD, and Pax3
revealed no defect in somite size and organisation in
Sepn1-/- embryos compared to wild-type (Figure 7A and
data not shown). Moreover, the expression pattern of
these factors was similar in both types of embryos (Figure
7A). Likewise, the expression of myosin heavy chain, a
marker of differentiated muscle cells, was unaltered when
visualized by immunohistochemistry in E11.5 and E13
deficient embryos (Figure 7B). These data were confirmed
by qRT-PCR and Western blot analyses that demonstrated
no modification of the myogenic factors expression in the
deficient embryos (Figure 7C and data not shown). Lastly,
the expression patterns of Scleraxis, involved in the estab-
lishment of myotendinous junctions [21], and of TrkA, a
neurotrophin receptor which was used as a marker of the
drg [22], appeared unmodified in Sepn1-/- embryos by
whole-mount ISH (Figure 7A).
Discussion
In this study, we characterized for the first time the precise
spatio-temporal expression pattern of the murine Sepn1
gene, the homolog of SEPN1 involved in several forms of
early onset myopathies in humans. We showed that Sepn1
is expressed early during embryogenesis and strongly
down-regulated before birth. We also demonstrated that,
in most isolated tissues, Sepn1 expression exhibited lim-
ited variations at the transcript levels between pre- and
post-natal stages, but significant changes at the protein
levels were detected, thereby pointing to a major post-
transcriptional regulation of this gene. Of particular inter-
est are some specific tissues where a significant increase in
the expression of transcript was observed between E18
and postnatal day 1 (for kidney) or older mice (for the
brain), whereas an almost 80% decrease in the protein
levels was detected between equivalent stages. Despite the
lack of data concerning the developmental expression pat-
tern of Sec insertion factors, one regulatory mechanism,
inherent to selenoproteins, may be based on the availabil-
ity of these specific factors. Indeed, this complex machin-
ery may exhibit spatial and temporal regulation,
associated with a hierarchy in the synthesis of selenopro-
teins, leading to potential fine tuning of each selenopro-
tein in both physiological and selenium deprivation
conditions [23-26]. It is thus conceivable that SelN expres-
sion is modulated depending on its requirements and bio-
logical roles in each tissue at the various developmental
stages. Notably, we reported recently that the loss of inter-
action between the SECIS sequence and SBP2 abolished
SelN translation and also led to the degradation of SEPN1
mRNA [20]. Therefore, modifying the interaction with the
translational machinery may also affect Sepn1 transcript
stability in mouse. Hence, whether the regulation of SelN
during development depends on the availability of Sec
insertion factors remains questionable.
Another regulatory pathway could involve microRNAs,
recently reported as major factors for translation modula-
tion without mRNA expression perturbation [27]. Their
importance in several developmental mechanisms has
already been well established in most species, including
vertebrates [28]. We determined that the Sepn1 sequence
is a potential target for several microRNAs (PC, PG, per-
sonal communication); however, their biological rele-
vance and developmental involvement are not yet
established. On the other hand, SelN expression may also
be modulated by protein degradation or cleavage, as
reported for different proteins located within the endo-
plasmic reticulum membrane [29]. Such proteolysis was
suggested in the study of Deniziak et al. who observed a
potential cleavage product by Western blot that correlates
with reduced expression of SelN in zebrafish [18]. How-
ever, it was not investigated whether the degradation was
physiological, or rather linked to the experimental condi-
tions. Lastly, it is noteworthy that in some tissues, such as
kidney and liver, in which similar dynamics were
observed for protein and transcript expression, the gene is
most likely regulated at the transcriptional level, although
the factors involved are not known yet. Taken together,
our findings reveal that complex transcriptional and trans-
lational regulation networks may be associated with the
expression of SelN during development.
The expression pattern presented herein provides interest-
ing insights into the physiological functions of SelN.
Indeed, in all of the tissues examined except liver, highBMC Developmental Biology 2009, 9:46 http://www.biomedcentral.com/1471-213X/9/46
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levels of SelN expression were limited to a particular tem-
poral window, with a pronounced and progressive reduc-
tion observed between E18 and post-natal stages. These
results are consistent with those obtained in zebrafish
where a strong reduction of the expression was detected
during somites differentiation [17,18], and in humans
where a decrease was observed between foetal and adult
tissues [16]. This developmental pattern suggests that
SelN may participate in the maturation of cells and organs
from mid-gestation to perinatal stages. This notion is sup-
ported by the observation that SelN expression decreased
during both human [16] and murine myoblast differenti-
ation in culture. To our knowledge, there is no similar
expression pattern reported for other selenoproteins but
this may be at least partly due to the lack of studies focus-
ing on the expression pattern of these proteins in mam-
mals. Notwithstanding, in mouse, selenoprotein W
(SelW) was found to be expressed early during develop-
ment (E6) and to decrease during myoblast differentia-
tion, but comparisons between pre- and post-natal stages
in different tissues were not reported [7]. Moreover, in
zebrafish, SelM was the only other selenoprotein reported
to be expressed at the transcript levels in somites [6].
Based on the previous data obtained in humans and
zebrafish, a potential link between SelN and cell prolifer-
ation has already been proposed [16]. At mid-gestation
stages, we found that Sepn1 is expressed in the mesen-
chyme located under the ectoderm. Taking into account
our previous work showing high expression in fibroblasts
[16], we attributed this expression to mesenchymal cells
that share the general features of fibroblasts. Moreover, we
first hypothesized that this pattern could correlate with a
higher proportion of proliferative cells in this area. How-
ever, BrdU staining in E11.5 embryos did not reveal a
higher mitotic activity in this region (data not shown).
Likewise, in mature somites, Sepn1  expression was
detected in the myotome, mainly composed of post-
mitotic cells that have initiated the myogenic program,
while its expression was almost undetectable in the der-
momyotome where most cells are proliferating [30].
Therefore, at least during mouse embryogenesis, there is
no straightforward correlation between Sepn1  and cell
proliferation.
The early expression detected in somites correlates with
ISH results obtained in zebrafish [6]. Moreover, in mice,
the restricted expression found in myotome indicates that
Sepn1 is expressed by muscle precursors and maturating
myocytes but less or not by uncommitted cells. Interest-
ingly, in contrast to observations performed on zebrafish
embryos knock-down for sepn1 expression [17,18], we did
not detect any defects in somite organisation nor in myo-
genic factors expression, at mid-gestation stages, in Sepn1
mutant embryos. This suggests that SelN is dispensable
for somitogenesis as well as the early waves of myogenesis
in mouse. The simplest explanation would be that redun-
dant activities exist in mouse, which may be less active in
others animals. Due to the common reactivity of seleno-
proteins conferred by the Sec residue, one can hypothesize
that some functional redundancy may exist within the
protein family. Therefore, it would be interesting to fur-
ther investigate other selenoproteins located in the endo-
plasmic reticulum, such as Sep15, SelS and SelM, and/or
expressed predominantly during embryogenesis, like
Gpx6 [2]. In addition, among the selenoproteins
expressed in skeletal muscles, SelW is particularly interest-
ing because of its dynamic expression during muscle mat-
uration and its presumed association with white muscle
disease [31]. Quantification of several selenoproteins
expression by qRT-PCR revealed no difference between
E12.5 wild-type and mutant Sepn1-/- whole embryos (data
not shown). However, additional experiments, including
older mice and protein analyses, need to be performed to
resolve this issue.
Lastly, the barely detectable levels of SelN expression
found in mature muscles fit with the previous observa-
tions in human tissues [16] and suggest a limited role for
the protein at these stages. This contrasts with the progres-
Sepn1 expression during murine myoblast differentiation Figure 3
Sepn1 expression during murine myoblast differenti-
ation. A: Sepn1 qRT-PCR on cDNA from C2C12 myoblasts 
(Mb) and myotubes after 2 and 3 days (2 d/3 d) in differentia-
tion medium. Hprt served for normalization. A two fold 
reduction of Sepn1 expression was observed in myotubes 
compared to undifferentiated cells. B: SelN Western blot 
analysis on proteins from C2C12 cells (Mb, 2 d, and 3 d), 
normalized to α-tubulin. Note that the decrease of SelN 
expression between myoblasts and myotubes is even more 
marked compared to transcript quantification. *, p < 0.05.
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sive evolution of the pathology with age. One reason may
be that SelN deficiency during muscle development leads
to increased fragility of the tissue that worsens during
aging. Another non necessarily exclusive hypothesis is
that SelN is required in mature muscles subjected to con-
stant tonic contractions, since the pathology affects more
severely the respiratory and postural muscles. However,
our data showing similar expression levels in muscles as
different as quadriceps and diaphragm do not appear to
sustain this hypothesis. The characterization of Sepn1 defi-
cient mice, from later developmental stages to adult ages,
will constitute a major point of investigation in order to
better understand SelN function in muscle physiology
and the remaining paradox regarding its almost ubiqui-
tous expression and the specific muscular phenotypes.
Taking into account the recent studies suggesting a role for
SelN in the regulation of ryanodine receptors (RyR) activ-
ity [17,19], it is interesting to try and correlate their devel-
opmental activity with the expression pattern of SelN
described herein. RyR1 expression was reported in mouse
myotome as early as E9.5 by ISH [32] but significant pro-
tein expression was only detected at late embryonic stages
in rodents [33,34]. In addition, RyR1 expression greatly
increases two weeks after birth and becomes predominant
in mature muscles, therefore differing from SelN pattern
[33-35]. In contrast, RyR3 expression strongly decreases at
postnatal day 15 and it is almost undetectable in most
adult tissues [33-36]. Furthermore, it was reported that its
expression is exclusively maintained in highly active mus-
cles, such as diaphragm or neck muscles [37] in which it
may amplify calcium signals [38,39]. Interestingly, these
tissues correspond to the most affected muscles in SEPN1-
related myopathies. Taken together, this comparison
between RyR channels and SelN weakens the proposed
functional link between RyR1 and SelN, but suggests a
closer relationship between RyR3 and SelN. This is further
substantiated by our ISH results. Indeed, Sepn1 staining
was detected in the dorsal root ganglia which correspond
to neural crest derivatives containing cell bodies of sensi-
tive neurons, where a CICR mechanism was reported and
associated with RyR3 channels [40,41]. We note also that
Sepn1 was expressed in the sub-ectodermal mesenchyme,
a region known to dynamically participate in cell migra-
tion during development, with active calcium waves
involved in this process. Finally, the precise role of SelN in
the regulation of RyR channels and the existence of other
substrates remain largely unsolved.
Conclusion
This is the first study that establishes the precise spatio-
temporal expression pattern of selenoprotein N in mam-
mals, with both transcript and protein analyses at the dif-
ferent developmental stages. We showed that SelN is
expressed early during mouse embryogenesis, particularly
in somites and muscle precursors. Nevertheless, it appears
to be dispensable for correct somitogenesis and expres-
sion of myogenic factors at mid-gestation stages. We also
demonstrated that SelN expression pattern is wide-spread
and is subject to post-transcriptional regulations which
lead to the significant reduction of its protein expression
levels during the perinatal period. Our results suggest
important functions for SelN during the maturation of
cells and organs. Further investigations should focus on
the particular developmental window when SelN is
strongly expressed, to determine the involvement of this
selenoprotein in muscle physiology and to unveil the
pathophysiological mechanisms leading to muscle altera-
tion in SEPN1-related myopathies.
Methods
Cell culture
Mouse C2C12 cells were grown in an humidified atmos-
phere of 5% CO2, at 37°C, in Dulbecco's modified Eagle's
Specificity of the Sepn1 probes Figure 4
Specificity of the Sepn1 probes. A: Schematic represen-
tation of the murine (Sepn1) and human (SEPN1) mRNA. 
Exons and the SECIS sequence are represented by grey and 
black boxes, respectively. The human third exon, corre-
sponding to an Alu sequence, is represented by a white box. 
Target sequences of Pr1 and Pr2 ISH probes are shown 
above the schema. B: Northern blot analysis, using the Pr1 
probe, of RNA extracted from human control fibroblasts (c) 
and fibroblasts from a RSMD1 patient with a homozygous 
premature stop codon, leading to SEPN1 mRNA degradation 
(p).  -actin is used as a reference. A 4.2/4.3 kb band was 
observed in control fibroblasts but not in RSMD1 fibroblasts, 
validating the specificity of Pr1 for SEPN1 transcripts. C: 
Northern blot analysis of RNA from mouse E12 (mE12) and 
E18 (mE18) whole embryos shows a single 3.4 kb band cor-
responding to Sepn1 transcript.BMC Developmental Biology 2009, 9:46 http://www.biomedcentral.com/1471-213X/9/46
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medium (DMEM, Invitrogen) supplemented with 20%
foetal calf serum (FCS, Invitrogen), 2 mM gentamycine
(Invitrogen). Differentiation into myotubes was induced
by switching the medium to DMEM supplemented with
1% FCS.
Mice and genotyping
C57Bl/10 mice were euthanized with isoflurane and tis-
sues were dissected at various ages. Embryos were
obtained from gestating females of the Sepn1 knock-out
lineage (Rederstorff et al., article in preparation) between
embryonic days 5.5 (E5.5) and 18.5 (E18.5), the morning
of the vaginal plug indicating the stage E0.5. For in situ
hybridization, embryos were dissected at 4°C in phos-
phate buffer saline (PBS) and freed from their extra-
embryonic membranes. At E9.5 and older stages, the neu-
ral tube was pierced open at the level of the brain to facil-
itate exchange of solutions. Embryos were fixed overnight
at 4°C, in 4% paraformaldehyde (PFA), dehydrated in
methanol and conserved at -20°C. DNA extraction was
carried out for genotyping with the Wizard Genomic DNA
Isolation System (Promega) according to the manufac-
turer's recommendations. All animal studies were per-
formed in accordance with the European Union
guidelines for animal care and approved by the local eth-
ical committee on animal experimentation.
Total RNA extraction and first-strand cDNA synthesis
Whole embryos and isolated tissues were frozen in liquid
nitrogen. Total RNA was extracted using the RNeasy
Fibrous Tissue Mini Kit (Qiagen) according to the manu-
facturer's instructions. Total RNA was also extracted from
cultured human fibroblasts (control and RSMD1 patient
with a c.1446delC homozygous mutation) by Trizol (Inv-
itrogen) procedure as previously described [11]. RNA
yield and quality were assessed with the Nanodrop system
(Thermo Scientific) and on the 2100 Bioanalyzer (Agilent
Technologies). RNA samples with a RIN (RNA Integrity
Number) superior to 8 were used for quantification.
cDNA was synthesized from 500 ng of RNA with random
hexamer primers using the SuperScript First-Strand Syn-
thesis System for RT-PCR (Invitrogen).
Quantitative PCR (qPCR)
Sepn1 transcripts were quantified by real time PCR using
the following primers: 5'GCTTTCCTGTAGAGATGATG3'/
5'GCCCCGCCGGAGTCCTTC3'. qPCR were performed on the
LightCycler480 System (Roche) using the LighCycler480
SYBR Green I Master mix (Roche). The program included
an initial denaturation step of 8 min at 95°C, followed by
40 amplification cycles of denaturation at 95°C for 10 sec,
hybridization at 63°C for 15 sec, and elongation at 72°C
for 15 sec. Quantification of additional genes was per-
formed similarly with the following primers: 18s:
5'ACCTGGTTGATCCTGCCAGT3'/5'CTCACCGGGTTGGTTTTGAT3';
Hprt:5'AAGCAGATGGCCACAGAACT3'/5'ACCCCACGAAGTGTTGG
ATA 3'. Data were analyzed using the LightCycler480 anal-
ysis software (Roche).
RNA probes synthesis and whole-mount In Situ 
Hybridization (ISH)
Two digoxigenin (DIG) labeled riboprobes (Pr1/Pr2) were
generated from Sepn1 PCR fragments obtained from total
murine cDNA with the following primers: Pr1:
5'TCCTAGATGAGGACGGCAAC3'/5'GGTCCTCAAAGCTGGATGA G3';
Pr2: 5'CGCCCATCCTCACTCTCCTC3'/5'TCCAGTCCACT CCCTAT
TCACA3'. Fragments were cloned in the pGEM-T vector
(Promega). Antisense and sense probes were synthesized
using the DIG RNA Labeling Kit (Roche) with T7 or SP6
RNA polymerase. Sense probes were used as negative con-
trols. Yield and quality of the probes were estimated by
electrophoresis and dot blot compared to a standard (β-
actin probe  Roche). MyoD, Myf5, Scleraxis and TrkA probes,
previously described [42,43], were also used for whole
mount ISH.
Whole embryo In Situ Hybridization
In situ hybridizations (ISH) were performed on embryos
aged from E8.5 to E11.5, as previously described [43].
Briefly, after rehydration, embryos were treated with 10
μg/ml proteinase K (Qiagen) at room temperature, from
10 to 30 min according to their age and fixed in 4% PFA.
Embryos were incubated for more than 1 h in hybridiza-
tion buffer (50% formamide, 1.3× SSC pH 5, 50 μg/ml
SelN deficiency in the murine model Figure 5
SelN deficiency in the murine model. Sepn1 expression 
analyzed by qRT-PCR (A) and Western blot (B) performed 
on whole E12.5 littermate embryos: wild-type (+/+), hetero-
zygous (+/-) and homozygous mutants (-/-). 18s gene and α-
tubulin were used for normalization. Sepn1 transcript 
expression was almost abolished in the homozygous mutants 
and SelN was undetectable by Western blot in these mice. *, 
p < 0.05.
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Sepn1 whole mount in situ hybridization between E8.5 and E11.5 Figure 6
Sepn1 whole mount in situ hybridization between E8.5 and E11.5. A: E8.5 wild-type embryos hybridized with sense (a) 
and antisense (b-f) Sepn1 Pr1 probes. No signal was detected with sense probes (a). With the antisense Pr1 probe, all the 
somites appeared strongly stained (broken arrow  panel c). Sectioning with a vibratome revealed expression also in the 
branchial arches (d) and the neural tube (f). Note that no signal was observed in the heart (e). B: E9.5 wild-type (g, h) and 
Sepn1-/- (i) embryos hybridized with the Sepn1 antisense Pr1 probe. Broken arrow in (g) shows stained somites. Mesenchymal 
staining (black arrowhead) was revealed within vibratome sections (h: section in the forebrain). No signal was seen within 
the mutant embryos (i). C: E10.5 (j) and E11.5 (k-m) wild-type embryos hybridized with the Sepn1 antisense Pr1 probe. Dorsal 
region of wild-type embryos is shown in (m). (n-s) High magnification of vibratome sections performed in the trunk (n-q), the 
head (r), and the limb bud (s). Inset p corresponds to a higher magnification of the outlined region in o. The section plans are 
indicated in the schema. Sepn1 expression was detected in the sub-ectodermal mesenchyme (black arrowhead), the myo-
tome (arrow) and the dorsal root ganglia (*). Note that overt staining was not observed in the dermomyotome (white 
arrowhead) nor in the heart. No signal was detected in Sepn1-/- embryos hybridized with Sepn1 antisense probe (t). ba: 
branchial arches; drg: dorsal root ganglia (*); ec: ectoderm; fl: forelimb; he: heart; hl: hindlimb; nt: neural tube; so: somite; ve: ventricle. 
Scale bars in (A) = 200 μm, in (B, C) = 400 μm.
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yeast RNA, 5 mM EDTA pH 8, 0.2% Tween-20, 0.5%
CHAPS, 100 μg/ml heparin) and then overnight with the
appropriate probe at 0.5 to 2 μg/ml, at 69°C. Embryos
were successively washed in hybridization buffer, in 1:1
hybridization buffer/MABT (100 mM maleic acid, 150
mM NaCl, 1% Tween-20), and finally in MABT. After
blocking in MABT, 2% Blocking Reagent (Roche), 20%
inactivated goat serum (Invitrogen) for more than 1 h at
room temperature, embryos were incubated overnight at
4°C in alkaline phosphatase conjugated anti-DIG anti-
body (1:2000  Roche). Revelation was obtained with the
BM Purple solution (Roche) at room temperature and/or
at 4°C, during different time laps depending on the
probe. Vibratome sections (50 to 80 μm) were performed
after inclusion of the embryos in 10% sucrose overnight at
4°C and then in 20% gelatin.
Northern Blotting
30 μg of total RNA were resolved on 1% formaldehyde
agarose gel and blotted overnight onto a positively
charged nylon membrane (Roche). RNA were UV cross-
linked to the membrane during 3 min. Membranes were
hybridized overnight at 68°C with diluted probe (100 ng/
ml) in hybridization buffer (DIG Easy Hyb buffer  Roche)
and then rinsed in 2× SSC, 0.1% SDS at room temperature
and in 0.1× SSC, 0.1% SDS at 68°C. Membranes were
blocked in Blocking Reagent (Roche) diluted in 0.1 M
maleic acid, 0.15 M NaCl, pH 7.5, and then incubated
with alkaline phosphatase conjugated anti-DIG antibody
(Roche) in maleic acid buffer. After incubation in detec-
tion buffer (0.1 M Tris-HCl, 0.1 M NaCl, pH 9.5), signals
were obtained with the CDP-star, ready-to-use buffer
(Roche) on the ChemImager system (Alpha Innotech).
Protein extraction and Western blot analysis
Frozen tissues were ground in liquid nitrogen and homog-
enized in protein extraction buffer (80 mM Tris-HCl, pH
6.8, 10% SDS, 120 mM sucrose, 10 mM EDTA, 1 mM
PMSF and 1 mM benzamidine). Homogenates were incu-
bated 10 min at 55°C, sonicated twice and quantified
with the BCA Protein Assay (Pierce). 60 μg of proteins
were electrophoretically separated in 8% polyacrylamide
SDS gel and transferred to a polyvinylidene difluoride
membrane (Invitrogen). Membranes were immuno-
probed with the following primary antibodies: rabbit
anti-SelN (ab137 [16]), mouse anti-tubulin α (Sigma
T5168), rabbit anti-actin (Sigma A2066), rabbit anti-
MyoD (Santa Cruz sc-304), rabbit anti-myogenin (Santa
Cruz sc-576), rabbit anti-Myf5 (Santa Cruz sc-302) and
mouse anti-MyHC (ATCC, MF20). They were then incu-
bated with HRP-conjugated secondary antibodies (Dako).
Signals were detected with chemiluminescent HRP sub-
strate (Immobilon Western  Millipore) on the SynGene
instrument (Ozyme) and quantified with the ImageJ soft-
ware.
Immunohistochemistry
After rehydration, E12.5 whole embryos were equilibrated
in 15% sucrose overnight at 4°C. They were then frozen
in liquid nitrogen-cooled isopentane. Ten μm cryostat sec-
tions were fixed in 4% PFA, rinsed in 0.1 M glycine, and
incubated in methanol at -20°C. They were then placed in
boiling 0.01 M citric acid for 10 min to achieve antigen
retrieval. Sections were blocked in 3% IgG free bovine
serum albumin (BSA  Jackson ImmunoResearch) over-
night at 4°C and with ChromoPure Mouse IgG, Fab Frag-
ments (Jackson ImmunoResearch) for 30 min. Sections
were then incubated in 3% IgG free BSA, 0,1% Triton X-
100, with primary antibodies (MyHC: monoclonal mouse
ATCC MF20-1/100; laminin: polyclonal rabbit Abcam
ab11575-1/1000) for 3 h at room temperature. Alexa
Fluor secondary antibodies (goat anti-mouse A568, goat
anti-rabbit A488; Jackson ImmunoResearch) were incu-
bated on slides for 90 min at room temperature. Sections
were rinsed, mounted in Vectashield DAPI (Vector) and
Somitogenesis in wild-type and Sepn1-/- embryos Figure 7
Somitogenesis in wild-type and Sepn1-/- embryos. A: 
Whole mount in situ hybridization, and corresponding 
vibratome sections, against Myf5, MyoD, Scleraxis (E11.5) and 
TrkA (E13) performed on Sepn1+/+ and Sepn1-/- embryos. No 
difference was observed in somite organisation and size 
(black fragments) between wild-type and mutants embryos. 
The expression pattern of the tested factors appeared unal-
tered in absence of SelN. Vibratome sections correspond to 
the trunk level for Myf5 and to the limb bud for MyoD. B: 
Immunostaining against myosin heavy chain on E11.5 and E13 
wild-type and deficient embryos. The expression patterns 
were identical between the embryos. Myotome is outlined 
with a white broken line. C: Western blot analysis against 
myogenic factors, performed on proteins from wild-type and 
deficient E12.5 whole embryos, revealed no alteration of 
their expression in the mutant embryos. α-tubulin was used 
for normalization. Scale bars = 400 μm. d: drg; nt: neural tube.
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observed with an Axiophot microscope (Zeiss). Images
were captured using the Metaview software (Ropper Scien-
tific).
Statistical analyses
Results represent Means ± SD. Comparisons between two
groups were performed using a Student's t-test or a Mann-
Whitney rank sum test depending on the normal distribu-
tion of data, with a 0.05 level of confidence accepted for
statistical significance. Multiple group comparison was
performed by one way ANOVA with Dunn's pairwise pro-
cedures (p < 0.05).
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